psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling
文献类型：期刊论文
| 作者 | Ding, Jin1; Wen, Wen1; Xiang, Daimin1; Yin, Peipei1,2; Liu, Yanfang3; Liu, Chang2; He, Guoping1; Cheng, Zhuo1; Yin, Jianpeng5; Sheng, Chunquan4 |
| 刊名 | oncotarget
 |
| 出版日期 | 2015-05-10 |
| 卷号 | 6期号:13页码:11627-11639 |
| 关键词 | psi-Bufarenogin hepatocellular carcinoma epithelial growth factor receptor hepatocyte growth factor receptor |
| 英文摘要 | resistance of hepatocellular carcinoma (hcc) to existing chemotherapeutic agents largely contributes to the poor prognosis of patients, and discovery of novel anti-hcc drug is in an urgent need. herein we report psi-bufarenogin, a novel active compound that we isolated from the extract of toad skin, exhibited potent therapeutic effect in xenografted human hepatoma without notable side effects. in vitro, psi-bufarenogin suppressed hcc cells proliferation through impeding cell cycle progression, and it facilitated cell apoptosis by downregulating mcl-1 expression. moreover,psi-bufarenogin decreased the number of hepatoma stem cells through sox2 depression and exhibited synergistic effect with conventional chemotherapeutics. mechanistic study revealed that psi-bufarenogin impaired the activation of mek/erk pathway, which is essential in the proliferation of hepatoma cells. psi-bufarenogin notably suppressed pi3-k/akt cascade, which was required in psi-bufarenogin-mediated reduction of mcl-1 and sox2. psi-bufarenogin inhibited the auto-phosphorylation and activation of epithelial growth factor receptor (egfr) and hepatocyte growth factor receptor (c-met), thereafter suppressed their primary downstream cascades raf/mek/erk and pi3-k/akt signaling. taken together, psi-bufarenogin suppressed hcc growth via inhibiting, at least partially, receptor tyrosine kinases-regulated signaling, suggesting that psi-bufarenogin could be a novel lead compound for anti-hcc drug. |
| WOS标题词 | science & technology ; life sciences & biomedicine |
| 类目[WOS] | oncology ; cell biology |
| 研究领域[WOS] | oncology ; cell biology |
| 关键词[WOS] | advanced hepatocellular-carcinoma ; cell lung-cancer ; stem-cells ; interaction chromatography ; apoptosis ; met ; bufadienolides ; identification ; proliferation ; activation |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000359006400073 |
| 公开日期 | 2016-05-09 |
| 源URL | [http://cas-ir.dicp.ac.cn/handle/321008/146429]  |
| 专题 | 大连化学物理研究所_中国科学院大连化学物理研究所 |
| 作者单位 | 1.Second Mil Med Univ, Int Cooperat Lab Signal Transduct, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China 2.Shanghai Inst Pharmaceut Ind, Dept Pharmacol, Shanghai, Peoples R China 3.Chinese Acad Sci, Dalian Inst Chem Phys, Key Lab Separat Sci Analyt Chem, Dalian, Peoples R China 4.Second Mil Med Univ, Coll Pharm, Shanghai, Peoples R China 5.Natl Ctr Drug Screen, Shanghai, Peoples R China 6.Jinan Univ, Coll Pharm, Guangzhou, Guangdong, Peoples R China 7.Natl Ctr Liver Canc, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Ding, Jin,Wen, Wen,Xiang, Daimin,et al. psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling[J]. oncotarget,2015,6(13):11627-11639. |
| APA | Ding, Jin.,Wen, Wen.,Xiang, Daimin.,Yin, Peipei.,Liu, Yanfang.,...&Wang, Hongyang.(2015).psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.oncotarget,6(13),11627-11639. |
| MLA | Ding, Jin,et al."psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling".oncotarget 6.13(2015):11627-11639. |
入库方式： OAI收割
来源：大连化学物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。